The average fluorescence intensity of anti-STAU2 was not significantly different among WBCs obtained from normal females with 1 to 3 mammograms, but an increasing trend was noted from early-stage to late-stage breast cancer patients (p = 0.0008) (Fig. 4C). The gene discussed is STAU2; the disease is breast carcinoma.